favorite Donate

Myeloma Clinical Trials: Rafael Fonseca, MD and Brian McMahon, Founder of SparkCures

Posted: Nov 14, 2019

Myeloma Clinical Trials: Rafael Fonseca, MD and Brian McMahon, Founder of SparkCures image

Treatment Advances

Dr. Rafael Fonseca from the Mayo Clinic recently had a conversation Brian McMahon, founder and CEO of SparkCures, about myeloma clinical trials. You can view their interview below, where they discuss the importance of clinical trials, how to search for them, and how to discuss them with your doctors.

If you’re interested in finding out more about clinical trials, follow the link to create your free HealthTree account, which is linked together with SparkCures.

Dr. Rafael Fonseca from the Mayo Clinic recently had a conversation Brian McMahon, founder and CEO of SparkCures, about myeloma clinical trials. You can view their interview below, where they discuss the importance of clinical trials, how to search for them, and how to discuss them with your doctors.

If you’re interested in finding out more about clinical trials, follow the link to create your free HealthTree account, which is linked together with SparkCures.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.

More on Treatment Advances

FDA Advisory Panel Supports Daratumumab for High-Risk Smoldering Multiple Myeloma image

FDA Advisory Panel Supports Daratumumab for High-Risk Smoldering Multiple Myeloma

New Treatment for Reducing the Risk of Graft Versus Host Disease After Allogeneic Stem Cell Transplant image

New Treatment for Reducing the Risk of Graft Versus Host Disease After Allogeneic Stem Cell Transplant

Is It Possible To Be Resistant to Lenalidomide (Revlimid)? image

Is It Possible To Be Resistant to Lenalidomide (Revlimid)?

FDA Grants Fast Track for ISB 2001: A Trispecific Antibody for Relapsed/Refractory Multiple Myeloma image

FDA Grants Fast Track for ISB 2001: A Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Could Teclistamab Help Newly Diagnosed Myeloma Patients Live Longer After Transplant? image

Could Teclistamab Help Newly Diagnosed Myeloma Patients Live Longer After Transplant?

New GenoPredicta Test Brings More Accurate Diagnosis and Treatment Options for Multiple Myeloma image

New GenoPredicta Test Brings More Accurate Diagnosis and Treatment Options for Multiple Myeloma

See More Treatment Advances

Trending Articles

Could Teclistamab Help Newly Diagnosed Myeloma Patients Live Longer After Transplant?

Common Resources Used in Decision-Making for Relapsed/Refractory Multiple Myeloma Patients

Sexual Health and Multiple Myeloma: What Patients Need to Know

FDA Grants Fast Track for ISB 2001: A Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

Is It Possible To Be Resistant to Lenalidomide (Revlimid)?

Upcoming Events

An hour with Craig E. Cole, MD

An hour with Craig E. Cole, MD

May 27 / 8:30 EDT

Discover Cure Hub with the Roswell Park IMF support group

Discover Cure Hub with the Roswell Park IMF support group

May 28 / 18:00 EDT

HealthTree Connect to Cures in Macon, GA – Connect With Other Patients (In-Person Event)

HealthTree Connect to Cures in Macon, GA – Connect With Other Patients (In-Person Event)

May 31 / 10:00 EDT

Thanks to our sponsors:

Follow Us

Download our App

Download iOS App

Download Android App

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2025 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811